518 Discovery of MACO-355, a novel, first in mechanism ligand-blocking independent anti-LILRB1/2 monoclonal antibody for cancer therapy

Abstract

BackgroundMacrophages populate most solid tumors in large numbers and limit effective anti-tumoral immune responses.1 The immunoreceptor tyrosine-based inhibitory motifs (‘ITIMs’) containing leukocyte immunoglobulin-like receptors (LILR) B1 and LILRB2 are expressed...